Showing results (361-370 of 760) with videos related to
Sort By:
Pageof 76
JAMA Oncology|September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysisNikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.American Journal of Hematology|January 6, 2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA studyMaría Victoria Mateos, Paul G Richardson, Meletios A Dimopoulos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myelomaPierfrancesco Tassone, Paola Neri, Renate Burger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2013
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growthEmanuela Leone, Eugenio Morelli, Maria T Di Martino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myelomaAndrzej J Jakubowiak, Don M Benson, William Bensinger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2009
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemiaHai T Ngo, Abdel Kareem Azab, Mena Farag, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemiaSteven P Treon, Mark Hansen, Andrew R Branagan, et al.Cancer Research|December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myelomaLaurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.Cancer Research|February 20, 2007
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myelomaKlaus Podar, Marc S Raab, Giovanni Tonon, et al.Blood Cancer Discovery|June 28, 2021
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcareNicole Gormley, Lola Fashoyin-Aje, Trevan Locke, et al.Pageof 76